Corporate Strategy Lead

Immix Biopharma (Nasdaq: IMMX); Los Angeles (CA); On-site; USD 140,000 - 200,000; Full time

Job summary

Immix Biopharma, Inc. in Los Angeles is seeking a finance/strategy professional to build internal financial models and contribute to development strategy for the company’s therapeutic pipeline.

You will participate in shaping corporate strategy for potential new therapies and prepare proforma analyses to evaluate opportunities. The role requires experience in investment banking, equity research, private equity, or consulting, plus a background in biopharma strategy.

Qualifications

• Prior investment banking / equity research / private equity / management consulting experience.
• Experience analyzing biopharmaceutical strategies.
• Publications in Scientific Research; Good Laboratory Practices; early drug development experience a plus.

Responsibilities

• Create and complete internal financial models and presentations.
• Pipeline - Participate in determining development strategy for pipeline therapeutic candidates.
• Participate in developing corporate strategy for possible new therapeutic pipeline.
• Create and complete proforma models to evaluate opportunities.

Skills

Financial modeling

Corporate strategy

Presentation skills

Biopharma industry knowledge

Education

MD/PhD/MS preferred

Job description

• Create and complete internal financial models and presentations
• Pipeline - Participate in determining development strategy for pipeline therapeutic candidates
• Participate in developing corporate strategy for possible new therapeutic pipeline
• Create and complete proforma models to evaluate opportunities

What We Look For

• Prior investment banking / equity research / private equity / management consulting experience
• Prior experience analyzing biopharmaceutical strategies
• Prior Scientific Research Publications, Good Laboratory Practices, Experience in Early Drug Development a plus
• MD, PhD and/or MS a plus

About Immix

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.